Glucose News and Research

RSS

Ford researchers develop series of in-car health and wellness apps, services

Researchers at Ford have developed a series of in-car health and wellness apps and services aimed at monitoring people with chronic illnesses or medical disorders so they can manage their condition while on the go.

From Medtronic 10 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

First combination drug to treat type 2 diabetes and high cholesterol receives FDA approval

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

7 Oct 2011

Scientists discover rare genetic alteration responsible for hypoglycaemia

Cambridge scientists have identified the cause of a rare, life-threatening form of hypoglycaemia. Their findings, which have the potential to lead to pharmaceutical treatments for the disorder, were published today, 07 October, in the journal Science.

7 Oct 2011

People with good vitamin D supply at lower risk of developing Type 2 diabetes

Scientists at the Helmholtz Zentrum München have shown that people with a good vitamin D supply are at lower risk of developing Type 2 diabetes mellitus. The study, which was conducted in cooperation with the German Diabetes Center and the University of Ulm, will be published in the October edition of the renowned scientific journal Diabetes Care.

4 Oct 2011

Virtual 18F-FDG PET/CT bronchoscopy may accurately detect NSCLC metastases

For patients with non-small cell lung cancer (NSCLC) the accurate determination of the lymph node status before therapy is critical to develop an individualized treatment plan. Research from the October issue of the Journal of Nuclear Medicine highlights a new way for this information to be collected -- a virtual fly-through three-dimensional 18F-FDG PET/computed tomography (FDG-PET/CT) bronchoscopy that has high diagnostic accuracy for the detection of regional lymph node metastases.

4 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

FDA, other regulatory and international partners complete International Internet Week of Action

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

30 Sep 2011

Lin28/let-7 pathway plays an unexpected key role in type 2 diabetes

A pathway activated in cancer plays an unexpected key role in metabolic diseases like type 2 diabetes, according to a study by researchers at Children's Hospital Boston. Evidence that the Lin28/let-7 pathway influences the cellular response to glucose provides a unifying theme to perplexing data that associates human genetic variation with diabetes risk.

30 Sep 2011

Intensive blood glucose control therapy provides no added benefit against cognitive decline in older diabetics

Intensive control of blood sugar levels beyond standard targets provides no additional protection against cognitive decline in older people with diabetes than standard treatment, according to a national study coordinated by researchers at Wake Forest Baptist Medical Center.

29 Sep 2011

FOX06 protein contributes to liver overproduction of glucose in diabetes

Researchers at the John G. Rangos Sr. Research Center at Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine have identified a powerful molecular pathway that regulates the liver's management of insulin and new glucose production, which could lead to new therapies for diabetes.

29 Sep 2011

Aggressive glycemic control does not improve clinical outcomes for diabetic CABG patients

Surgeons from Boston Medical Center (BMC) have found that in diabetic patients undergoing coronary artery bypass graft (CABG) surgery, aggressive glycemic control does not result in any significant improvement of clinical outcomes as compared with moderate control.

28 Sep 2011

Physical activity improves arthritis symptoms in obese mice

Adding another incentive to exercise, scientists at Duke University Medical Center have found that physical activity improves arthritis symptoms even among obese mice that continue to chow down on a high-fat diet.

27 Sep 2011

UCSF, QuantiaMD develop new DiabetesIQ mobile phone app

A new interactive mobile phone app called DiabetesIQ, released this week, challenges people to test their knowledge of diabetes and to compete with one another as they learn about the complexities of the disease, which affects more than 25 million Americans, including 4 million Californians.

27 Sep 2011

Gene blockade could reverse type 2 diabetes: Study

Australian scientists report that they may be on the brink of reversing type 2 diabetes after a genetic discovery. The finding centers on how a particular gene responds to high-fat diets by disrupting insulin production in the pancreas and triggering diabetes.

26 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

Sleep deprivation may disrupt insulin secretion and glucose levels in obese teens

Obese teenagers who don't get the proper amount of sleep may have disruptions in insulin secretion and blood sugar (glucose) levels, say pediatric researchers. Their study suggests that getting a good night's sleep may stave off the development of type 2 diabetes in these adolescents.

21 Sep 2011

The obese can’t help but eat: Study

A new study suggests that brains of people who are obese may be wired differently for impulse control, such as resisting a doughnut when their blood sugar levels drop, compared with people who are not obese.

20 Sep 2011